In the CRL, the FDA stated that the data from KEYNOTE-524/Study 116 did not demonstrate a meaningful advantage over available therapies for unresectable or metastatic HCC.
[Cancer Management and Research] Researchers sought to determine if apatinib-related hypertension was a predictor of drug efficacy in patients with advanced HCC.
The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
The combination resulted in durable response in many patients.
[Journal of Hepatocellular Carcinoma] In this review, the authors discuss the use of imaging techniques and radiological biomarkers to monitor treatment response in patients with advanced HCC undergoing antiangiogenic therapy, a key to decisions on whether to continue treatment or initiate second-line therapy.